Sitemap > News > Oncology
Displaying 1 - 50 of 894 results
- FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
- Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
- Serenex Announces Initiation of Phase 1 Trial for Oral HSP90 Inhibitor, SNX-5422
- Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
- Celsion Completes Enrollment In Phase I Liver Cancer Study
- Epeius Biotechnologies Gains Fda Approval For Two New Clinical Trials Using Rexin-G (Tm) For Breast Cancer And Sarcoma
- Telik Reports Results of TELCYTA® ASSIST-3 Trail
- Telik Announces Top-Line Results of TELCYTA® ASSIST-2 Trial
- Telik Reports Results of TELCYTA® ASSIST-1 Trail
- Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
- Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
- Æterna Zentaris Presents Detailed Phase 1 Results for Anti-Cancer Compound AEZS-108 at ASCO Meeting
- ARIAD Presents Additional Efficacy Data on AP23573, Novel mTOR Inhibitor, in Phase 2 Advanced Sarcoma Trial
- ARIAD Presents Positive Efficacy Data On AP23573, Novel mTOR Inhibitor, in Phase 2 Metastatic Endometrial Cancer Trial
- Biweekly Xeloda® Dosing Regimen Is Well Tolerated in Advanced Breast Cancer
- Xeloda® Plus Avastin® Combination Delays Disease Progression in Women with Advanced Breast Cancer
- CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
- Clinical Data Suggest Potential Versatility of ALIMTA® (Pemetrexed for Injection)-Based Regimens in Lung Cancer
- Study Supports Activity of GEMZAR® (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
- Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
- EntreMed Presents Phase 2 Results for Panzem® Capsules in Multiple Myeloma
- Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
- Exelixis Reports Comprehensive XL880 Phase I Data At ASCO
- GlaxoSmithKline reports positive new data On Tykerb® (lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) annual meeting
- 8-year long-term data demonstrate prolonged overall survival and length of disease remission with BEXXAR®
- Investigational Drug CEDIRANIB (AZD2171) Shows Promise In Patients With Recurrent Glioblastoma (GBM)
- Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
- Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
- Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
- Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
- New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
- Millennium Introduces New Oncology Molecule with Activity in Broad Range of Cancer Models
- VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
- Millennium Advances Aurora A Kinase Program
- Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
- Pharmacyclics Announces Positive Final Results of Phase 2 Trial of Xcytrin(R) Plus Radiosurgery for Brain Metastases With Occult Tumors Detected in 24% of Patients
- Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin(R) in Recurrent, Metastatic Non-Small Cell Lung Cancer
- Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
- Poniard Pharmaceuticals Announces Results of Picoplatin Phase 2 Trial That Confirm and Extend Survival Benefit in Small Cell Lung Cancer
- Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
- PTC Therapeutics Presents Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
- RESULTS OF VEGF TRAP (AFLIBERCEPT) HIGHLIGHTED AT ASCO 2007 ANNUAL MEETING
- FOLFOX4 (ELOXATIN®-based chemotherapy) AFTER SURGERY IMPROVES OVERALL SURVIVAL IN PATIENTS WITH EARLY (STAGE III) COLON CANCER
- S-1, A NOVEL ORAL FLUOROPYRIMIDINE, WHEN COMBINED WITH CISPLATIN, DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS OVER S-1 ALONE
- THE ELOXATIN®-BASED REGIMEN (FOLFOX4) SIGNIFICANTLY IMPROVED PROGRESSION FREE SURVIVAL WHEN GIVEN BEFORE AND AFTER SURGERY IN PATIENTS WITH RESECTABLE LIVER METASTASES FROM COLORECTAL CANCER
- ELOXATIN® (oxaliplatin injection)-BASED CHEMOTHERAPY SETS NEW TREATMENT BENCHMARK IN PATIENTS WITH METASTATIC COLORECTAL CANCER
- UPDATED STUDY RESULTS REINFORCE SURVIVAL BENEFIT OF TAXOTERE® (DOCETAXEL) FOR MEN WITH ADVANCED, HORMONE-RESISTANT PROSTATE CANCER
- Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
- ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
- Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer.